Oral semaglutide, the first oral GLP-1 receptor agonsist, was approved by the FDA on Sept 20, 2019, becoming the only noninjectable formulation in the class.
Contamination of some lots of ranitidine (Zantac) led the Novartis Sandoz unit today to stop distribution of the drug while the issue is being investigated.
US adults with type 2 diabetes have acheived negligible change in blood glucose levels, blood pressure, LDL-C levels, and smoking status in the past 15 years, according to a new study.
Less than half of PCPs responding to a recent survey chose correct values for prediabetes screening tests and seemed unaware of other evidence-based recommendations for prediabetes.
US adults with diagnosed diabetes are no closer to treatment goals than they were in 2005, according to a new study.
Heavy smokers who quit remain at significantly increased CVD risk for up to 10 years or more, according to new research. Results suggest that current risk estimators may need revision.
Deaths related to synthetic opioids increased from approximately 3000 in 2013 to more than 30 000 in 2018. A new book warns there is more to come.
About 25% of patients with diabetes report asking a physician for a cheaper drug. Skipping doses and pill splitting are tactics used to cut costs.
Recent vaping behavior is the only commonality found among teens and young adults hospitalized in 2 midwestern states, for severe respiratory symptoms.
The first annual International Congress on the Future of Neurology convenes in New York City in September. Which thought leaders will be moderating?